Form 4: Disc Medicine Director Ratcliffe Acquires 10,000 Stock Options

Director Liam Ratcliffe of Disc Medicine, Inc. acquired 10,000 stock options on June 12, 2024, at an exercise price of $38.85.

Summary

• Liam Ratcliffe, a director of Disc Medicine, Inc., filed a Form 4 on June 14, 2024.
• The filing reports the acquisition of 10,000 stock options on June 12, 2024.
• The exercise price of the options is $38.85.
• The options vest upon the earlier of the company's 2025 annual meeting or the one-year anniversary of the grant date, contingent on continued service.
• Following the transaction, Ratcliffe beneficially owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is tied to the director's continued service and the company's 2025 annual meeting, suggesting a focus on long-term commitment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the actions of company directors and officers.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future prospects.

Key Dates